Document:

Exhibit 10.84

 

NEITHER
THE SECURITIES REPRESENTED BY THIS NOTE OR THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES
NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT
THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS
AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE SATISFACTORY TO
THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR APPLICABLE STATE SECURITIES LAWS.

 

 

 

PROMISSORY NOTE

 

	$23,600	 	Newark, New Jersey
	 	 	May 1, 2014

BioNeutral Group Inc., a Nevada
corporation (the “Company”), for value received hereby promises to pay to Ray Dunning or his registered assigns
(the “Holder”), the sum of $23,600, or such other amount as shall then equal the outstanding principal amount
hereof and all accrued and unpaid interest, as set forth below, on May 1, 2015 (the “Maturity Date”). Payment due
hereunder shall be made by wire transfer of immediately available funds, in lawful tender of the United States, to an account
designated in writing by the Holder.

 

1.Interest.
Until all outstanding principal and interest on this Note shall have been paid in full, interest on the unpaid principal balance
of this Note shall accrue as follows from the date of May 1, 2014. Interest shall accrue at the rate of eighteen percent (8%) per
annum (the “Initial Interest Rate”). Interest will be payable on the Maturity Date.

 

2.Events
of Default. If any of the events specified in this Section 3 shall occur (herein individually referred to as an “Event
of Default”), the Company agrees to give the Holder prompt written notice of such event. The Holder may, so long as such
condition exists or has not been cured during the applicable cure period (whether or not the Holder has received notice of such
event), declare the entire principal and unpaid accrued interest here on immediately due and payable, by notice in writing to the
Company; provided, that upon occurrence of an Event of Default specified in subsection (iv) below, all principal and interest shall
automatically become immediately due and payable in full:

 

(i)Failure by
the Company to make any payment hereunder when due, which failure has not been cured within ten (10) days following such due date;
or

 

    	

    	 

    

(ii)Any failure or inability to effect
a conversion of this Note into Common Stock as provided for in Section 5 hereof, if such failure continues for five (5) business
days after the request for conversion.

 

(iii) Any
breach by the Company of any material representation, warranty or covenant in this Note which results in a Material Adverse Effect
on the Company’s business, operations or financial condition; provided, that, in the event of any such breach, such breach
shall not have been cured by the Company within 30 days after the earlier to occur of (a) written notice to the Company of such
breach, or (b) the Company’s knowledge of such breach; or

 

(iv)The institution
by the Company of proceedings to be adjudicated as bankrupt or insolvent, or the consent by it to institution of bankruptcy or
insolvency proceedings against it or the filing by it of a petition or answer or consent seeking reorganization or release under
the federal Bankruptcy Act, or any other applicable federal or state law, or the consent by it to the filing of any such petition
or the appointment of a receiver, liquidator, assignee, trustee or other similar official of the Company, or of any substantial
part of its property, or the making by it of an assignment for the benefit of creditors, or the taking of corporate action by the
Company in furtherance of any such action; or

 

(v) If, within
sixty (60) days after the commencement of an action against the Company seeking any bankruptcy, insolvency, reorganization, liquidation,
dissolution or similar relief under any present or future statute, law or regulation, such action shall not have been resolved
in favor of the Company or all orders or proceedings thereunder affecting the operations or the business of the Company stayed,
or if the stay of any such order or proceeding shall thereafter be set aside, or if, within sixty (60) days after the appointment
without the consent or acquiescence of the Company of any trustee, receiver or liquidator of the Company or of all or any substantial
part of the properties of the Company, such appointment shall not have been vacated; or

 

3.Prepayment.
The Company shall have the right, at any time prior to the Maturity Date, to prepay any outstanding amount due to the Holder for
an amount equal to 100% of the unpaid principal amount of this Note along with any accrued interest.

 

4.1Notices
of Record Date, etc. In the event that the Company takes any of the actions specified in this section the Company will provide
notice to the Holder.

 

4.1.1Any taking by the Company
of a record of the holders of any class of securities of the Company for the purpose of determining the holders thereof who are
entitled to receive any dividend or other distribution, or any right to subscribe for, purchase or otherwise acquire any shares
of stock of any class or any other securities or property, or to receive any other right; or

 

4.1.2Any capital
reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any transfer of
all or substantially all of the assets of the Company to any other person or any consolidation or merger involving the Company;
or

 

    	2

    	 

    

 

4.1.3Any voluntary
or involuntary dissolution, liquidation or winding-up of the Company; the Company will mail to the holder of this Note at least
five (5) business days prior to the earliest date specified therein, a notice specifying:

 

4.1.3.1 The
date on which any such record is to be taken for the purpose of such dividend, distribution or right, and the amount and character
of such dividend, distribution or right; and

 

4.1.3.2 The
date on which any such reorganization, reclassification, transfer, consolidation, merger, dissolution, liquidation or winding-up
is expected to become effective and the record date for determining stockholders entitled to vote thereon.

 

5.Conversion. The Holder
shall have the right to convert the principal amount of this Note and all accrued but unpaid interest into Common Stock of the
Company on the Maturity Date at a conversion price equal to 50% of the average closing price of the Company’s common stock
for the 10 preceding days of the Maturity Date; provided, however, that in no event shall the Holder be entitled
to convert any portion of this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of
shares of Common Stock beneficially owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed
beneficially owned through the ownership of the unconverted portion of the Notes or the unexercised or unconverted portion of any
other security of the Borrower subject to a limitation on conversion or exercise analogous to the limitations contained herein)
and (2) the number of shares of Common Stock issuable upon the conversion of the portion of this Note with respect to which the
determination of this proviso is being made, would result in beneficial ownership by the Holder and its affiliates of more than
4.99% of the outstanding shares of Common Stock. For purposes of the proviso to the immediately preceding sentence, beneficial
ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and Regulations 13D-G thereunder, except as otherwise provided in clause (1) of such proviso, provided, further,
however, that the limitations on conversion may be waived by the Holder upon, at the election of the Holder, not less than
61 days’ prior notice to the Borrower, and the provisions of the conversion limitation shall continue to apply until such
61st day (or such later date, as determined by the Holder, as may be specified in such notice of waiver).

 

6.Assignment.
Subject to the restrictions on transfer set forth herein, the rights and obligations of the Company and the Holder of this Note
shall be binding upon and benefit the successors and assigns of the parties. This Note may not be assigned or transferred by the
parties except in accordance with the terms hereof.  This Convertible Note is nontransferable by the Note holder without
prior written approval of the Board of Directors of the Company.

 

7.Waiver and Amendment. Any provision of this Note
may be amended, waived or modified upon the written consent of the Company and the Holder.

 

8.Transfer
of this Note. With respect to any offer, sale or other disposition of this Note, the Holder will give written notice to the
Company prior thereto, describing briefly the manner thereof, together with a written opinion of such Holder’s counsel,
which counsel must be acceptable to the Company, to the effect that such offer, sale or other distribution may be effected without
registration or qualification (under any federal or state law then in effect). Promptly upon receiving such written notice and
opinion, the Company, as promptly as practicable, shall notify such Holder that such Holder may sell or otherwise dispose of this
Note, all in accordance with the terms of the notice delivered to the Company. Each Note thus transferred shall bear a legend
as to the applicable restrictions on transferability in order to ensure compliance with the Act, unless in the opinion of counsel
for the Company such legend is not required. The Company may issue stop transfer instructions to its transfer agent in connection
with such restrictions.

 

    	3

    	 

    

 

9.Treatment
of Note. To the extent permitted by GAAP, the Company will treat, account and report the Note as debt and not equity for accounting
purposes and with respect to any returns filed with federal, state or local tax authorities.

 

10.Notices.
Any notice, request or other communication required or permitted hereunder shall be in writing and shall be deemed to have been
duly given if personally delivered or if faxed with confirmation of receipt by telephone or if mailed by registered or certified
mail, postage prepaid, at the respective addresses of the parties as set forth in this Note. Any party hereto may by notice so
given change its address for future notice hereunder. Notice shall conclusively be deemed to have been given when personally delivered,
faxed, or when deposited in the mail in the manner set forth above and shall be deemed to have been received when delivered.

 

11.No
Stockholder Rights. Nothing contained in this Note shall be construed as conferring upon the Holder or any other person the
right to vote or to consent or to receive notice as a stockholder in respect of meetings of stockholders for the election of directors
of the Company or any other matters or any rights whatsoever as a stockholder of the Company; and no dividends or interest shall
be payable or accrued in respect of this Note or the interest represented hereby.

 

12.Usury.
This Note is hereby expressly limited so that in no event whatsoever, whether by reason of acceleration of maturity of the
loan evidenced hereby or otherwise, shall the amount paid or agreed to be paid to the Holder hereunder for the loan, use, forbearance
or detention of money exceed that permissible under applicable law. If at any time the performance of any provision of this Note
or of any other agreement or instrument entered into in connection with this Note involves a payment exceeding the limit of the
interest that may be validly charged for the loan, use, forbearance or detention of money under applicable law, then automatically
and retroactively, ipso facto, the obligation to be performed shall be reduced to such limit, it being the specific intent of the
Company and the Holder that all payments under this Note are to be credited first to interest as permitted by law, but not in excess
of (i) the agreed rate of interest set forth herein or therein or (ii) that permitted by law, whichever is the lesser,
and the balance toward the reduction of principal. The provisions of this Section 12 shall never be superseded or waived and shall
control every other provision of this Note and all other agreements and instruments between the Company and the Holder entered
into in connection with this Note.

 

13.Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey, excluding that
body of law relating to conflict of laws.

 

    	4

    	 

    

14.Heading;
References. All headings used herein are used for convenience only and shall not be used to construe or interpret this Note.
Except where otherwise indicated, all references herein to Sections refer to Sections hereof.

 

15.Waiver.
The Company hereby waives demand, notice, presentment, protest and notice of dishonor.

 

IN WITNESS WHEREOF,
the Company has caused this Note to be issued this 1st day of May 2014.

 

	 	BioNeutral Group, Inc.
	 	 	 
	 	By:	/s/ Mark Lowenthal
	 	Name:	Mark A. Lowenthal
	 	Title:	President and Chief
Executive Officer

 

    	5

    	 

    

 

CONVERSION FORM

 

TO: BioNeutral Group, Inc.

        211 Warren Street

        Newark,
New Jersey 07103

 

The undersigned, hereby irrevocably elects
to convert the principal amount and any accrued but unpaid interest on this Convertible Note at a conversion price of $____ per
share. The undersigned hereby agrees that upon conversion, the entire principal due on this Convertible Note shall be deemed fully
paid and the Convertible Note will be cancelled in full. The Company shall have no obligation with respect to any principal payments
after the Effective Date.

 

Instructions
for Registration of Stock

 

NAME: _______________________________________________________________________

 

 

ADDRESS: ___________________________________________________________________

 

 

TELEPHONE: ________________________________________________________________

 

 

EMAIL:  ___________________________________________________________________

 

 

AMOUNT TO BE CONVERTED $_________________________________________

 

 

DATED: ___________________________________________________________________

  

 

 

	 	 	 
	PRINT NAME	 	SIGNATURE
	 	 	 
	 	 	 
	 	 	 

 

 

6Exhibit 10.85

 

THE SECURITIES REPRESENTED BY THIS INSTRUMENT
HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE
OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY
ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

BIONEUTRAL GROUP, INC.

 

CONVERTIBLE PROMISSORY NOTE

 

	$15,000	 	May 31, 2013

 

1. Principal and Interest.

 

(a) BioNeutral Group, Inc.,
a Nevada corporation (the "Company"), for value received, hereby promises to pay to the order of DH Technical Consulting,
LLC (the "Investor" or the "Holder") the sum of Fifteen Thousand US dollars ($15,000).

 

(b) Upon repayment of This
Promissory Note (the "Note") an additional 8% interest bonus payment will be added to any unpaid balance per month. This
Note shall be payable upon demand June 30, 2013 (the "Demand Date"). Commencing on the Demand Date, all principal and
the interest bonus payment hereunder shall be payable by the Company upon demand made by the Holder or Investor.

 

(c) Upon payment in full
of the principal and bonus payment, this Note shall be surrendered to the Company for cancellation.

 

(d) The principal and bonus
payment under this Note shall be payable at the principal office of the Company and shall be forwarded to the address of the Holder
hereof as such Holder shall from time to time designate.

 

2. Attorney's Fees.
If the indebtedness represented by this Note or any part thereof is collected in bankruptcy, receivership or other judicial proceedings
or if this Note is placed in the hands of attorneys for collection after default, the Company agrees to pay, in addition to the
principal and the bonus payment payable hereunder, reasonable attorneys' fees and costs incurred by the Investor.

 

3. Conversion.

 

3.1 Voluntary Conversion.
In the event that the Note is not paid prior to the Demand Date, the Holder shall have the right thereafter, exercisable in whole
or in part, to convert the outstanding principal and bonus payment hereunder into a number of fully paid and nonassessable whole
shares of the Company's $.00001 par value common stock ("Common Stock") determined in accordance with Section 3.2 below.

 

    	 

    	 

    

 

3.2 Shares Issuable.
The number of whole shares of Common Stock into which this Note may be voluntarily converted ("Conversion Shares") shall
be determined by dividing the aggregate principal amount borrowed hereunder by $.01 (the "Note Conversion Price"); provided,
however, that, in no event, shall Holder be entitled to convert any portion of this Note in excess of that portion of this Note
upon conversion of which the sum of (1) the number of shares of Common Stock beneficially owned by Holder and its affiliates (other
than shares of Common Stock which may be deemed beneficially owned through the ownership of the unconverted portion of this Note
or the unexercised or unconverted portion of any other security of Maker subject to a limitation on conversion or exercise analogous
to the limitations contained herein) and (2) the number of shares of common stock issuable upon the conversion of the portion of
this Note with respect to which the determination of this proviso is being made, would result in beneficial ownership by Holder
and its affiliates of more than 9.9% of the outstanding shares of common stock of the Company. For purposes of the proviso to the
immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange
Act of 1934 and Regulation 13D-G thereunder, except as otherwise provided in clause (1) of such proviso. The number of shares of
Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion Amount (as defined below)
by the Note Conversion Price. The term “Conversion Amount” means, with respect to any conversion of this Note, the
sum of (1) the principal amount of this Note to be converted in such conversion plus, (2) at the Company’s option, accrued
and unpaid interest, if any, on such principal amount at the interest rate provided in this Note to the conversion date, provided,
however, that the Company shall have the right to pay any or all interest in cash.

 

3.3  Notice and Conversion
Procedures. If the Holder elects to convert this Note, the Holder shall provide the Company with a written notice of conversion
setting forth the amount to be converted. The notice must be delivered to the Company together with this Note. Within twenty (20)
business days of receipt of such notice, the Company shall deliver to the Holder certificate(s) for the Common Stock issuable upon
such conversion and, if the entire principal amount hereunder was not so converted, a new note representing such balance.

 

3.4  Other Conversion
Provisions.

 

(a)  Adjustment of Note Conversion
Price. In the event the Company shall in any manner, subsequent to the issuance of this Note, approve a reclassification involving
a reverse stock split and subdivision of the Company's issued and outstanding shares of Common Stock, the Note Conversion Price
shall forthwith be adjusted by proportionately increasing the Note Conversion Price on the date that such subdivision shall become
effective. In the event the Company shall in any manner, subsequent to the issuance of this Note, approve a reclassification involving
a forward stock split and subdivision of the Company's issued and outstanding shares of Common Stock, the Note Conversion Price
shall forthwith be adjusted by proportionately decreasing the Note Conversion Price on the date that such subdivision shall become
effective.

 

(b)  Common Stock Defined. Whenever
reference is made in this Note to the shares of Common Stock, the term "Common Stock" shall mean the Common Stock of
the Company authorized as of the date hereof, and any other class of stock ranking on a parity with such Common Stock. Shares issuable
upon conversion hereof shall include only shares of Common Stock of the Company.

 

    	2

    	 

    

 

3.5 No Fractional Shares.
No fractional shares of Common Stock shall be issued upon conversion of this Note. In lieu of the Company issuing any fractional
shares to the Holder upon the conversion of this Note, the Company shall pay to the Holder the amount of outstanding principal
hereunder that is not so converted.

 

4. Representations,
Warranties and Covenants of the Company. The Company represents, warrants and covenants with the Holder as follows:

 

(a)  Authorization; Enforceability.
All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution
and delivery of this Note and the performance of all obligations of the Company hereunder has been taken, and this Note constitutes
a valid and legally binding obligation of the Company, enforceable in accordance with its terms except (i) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors' rights
generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable
remedies.

 

(b)  Governmental Consents.
No consent, approval, qualification, order or authorization of, or filing with, any local, state or federal governmental authority
is required on the part of the Company in connection with the Company's valid execution, delivery or performance of this Note except
any notices required to be filed with the Securities and Exchange Commission under Regulation D of the Securities Act of 1933,
as amended (the "1933 Act"), or such filings as may be required under applicable state securities laws, which, if applicable,
will be timely filed within the applicable periods therefore.

 

(c)  No Violation.
The execution, delivery and performance by the Company of this Note and the consummation of the transactions contemplated hereby
will not result in a violation of its Certificate of Incorporation or Bylaws, in any material respect of any provision of any mortgage,
agreement, instrument or contract to which it is a party or by which it is bound or, to the best of its knowledge, of any federal
or state judgment, order, writ, decree, statute, rule or regulation applicable to the Company or be in material conflict with or
constitute, with or without the passage of time or giving of notice, either a material default under any such provision or an event
that results in the creation of any material lien, charge or encumbrance upon any assets of the Company or the suspension, revocation,
impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its
business or operations, or any of its assets or properties.

 

5. Representations and
Covenants of the Holder. The Company has entered into this Note in reliance upon the following representations and covenants
of the Holder:

 

(a)     Investment Purpose.
This Note and the Common Stock issuable upon conversion of the Note are acquired for investment and not with a view to the sale
or distribution of any part thereof, and the Holder has no present intention of selling or engaging in any public distribution
of the same except pursuant to a registration or exemption.

 

    	3

    	 

    

 

(b)  Private Issue.
The Holder understands (i) that this Note and the Common Stock issuable upon conversion of this Note are not registered under the
1933 Act or qualified under applicable state securities laws, and (ii) that the Company is relying on an exemption from registration
predicated on the representations set forth in this Section 8.

 

(c)  Financial Risk.
The Holder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks
of its investment, and has the ability to bear the economic risks of its investment.

 

(d)  Risk of No Registration.
The Holder understands that if the Company does not register with the Securities and Exchange Commission pursuant to Section 12
of the Securities Exchange Act of 1934 (the "1934 Act"), or file reports pursuant to Section 15(d) of the 1934 Act, or
if a registration statement covering the securities under the 1933 Act is not in effect when it desires to sell the Common Stock
issuable upon conversion of the Note, it may be required to hold such securities for an indefinite period. The Holder also understands
that any sale of the Note or the Common Stock which might be made by it in reliance upon Rule 144 under the 1933 Act may be made
only in accordance with the terms and conditions of that Rule.

 

6. Assignment. Subject
to the restrictions on transfer described in Section 9 below, the rights and obligations of the Company and the Holder shall be
binding upon and benefit the successors, assigns, heirs, administrators and transferees of the parties.

 

7. Waiver and Amendment.
Any provision of this Note may be amended, waived or modified upon the written consent of the Company and the Holder.

 

8. Transfer of This
Note or Securities Issuable on Conversion Hereof. With respect to any offer, sale or other disposition of this Note or securities
into which this Note may be converted, the Holder will give written notice to the Company prior. thereto, describing briefly the
manner thereof. Unless the Company reasonably determines that such transfer would violate applicable securities laws, or that
such transfer would adversely affect the Company's ability to account for future transactions to which it is a party as a pooling
of interests, and notifies the Holder thereof within five (5) business days after receiving notice of the transfer, the Holder
may effect such transfer. The Note thus transferred and each certificate representing the securities thus transferred shall bear
a legend as to the applicable restrictions on transferability in order to ensure compliance with the 1933 Act, unless in the opinion
of counsel for the Company such legend is not required in order to ensure compliance with the 1933 Act. The Company may issue
stop transfer instructions to its transfer agent in connection with such restrictions.

 

    	4

    	 

    

 

9. Notices. Any
notice, other communication or payment required or permitted hereunder shall be in writing and shall be deemed to have been given
upon delivery if personally delivered or three (3) business days after deposit if deposited in the USA's mail for mailing by certified
mail, postage prepaid, and addressed as follows:

 

	   If to Investor:	DH
Technical Consulting, LLC; Attn: David Hoenig	 
	 	91
Stratford Road	 
	 	East Brunswick, NJ 08816	 
	 	 	 
	              If to Company:	Mark Lowenthal	 
	 	BioNeutral Group, Inc.	 
	 	211 Warren St.	 
	 	Newark, NJ 07103	 

 

Each of the above addressees may change its
address for purposes of this Section by giving to the other addressee notice of such new address in conformance with this Section.

 

10. Governing Law.
This Note is being delivered in and shall be construed in accordance with the laws of the State of New Jersey, without regard to
the conflicts of laws provisions thereof.

 

11. Heading; References.
All headings used herein are used for convenience only and shall not be used to construe or interpret this Note. Except as otherwise
indicated, all references herein to Sections refer to Sections hereof.

 

12. Waiver by the Company.
The Company hereby waives demand, notice, presentment, protest and notice of dishonor.

 

13. Delays. No delay
by the Holder in exercising any power or right hereunder shall operate as a waiver of any power or right.

 

14. Severability.
If one or more provisions of this Note are held to be unenforceable under applicable law, such provision shall be excluded from
this Note and the balance of the Note shall be interpreted as if such provision was so excluded and shall be enforceable in accordance
with its terms.

 

15. No Impairment.
The Company will not, by any voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed
or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of
this Note and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the Holder
of this Note against impairment.

 

    	5

    	 

    

 

IN WITNESS WHEREOF, BioNeutral
Group, Inc. has caused this Note to be executed in its corporate name and this Note to be dated, issued and delivered, all on the
date first above written.

 

	 	BioNeutral Group, Inc.
	 	 	 
	 	By:	 
	 	Name:	 Mark Lowenthal
	 	Title:	 CEO and President
	 	 	 
	 	INVESTOR
	 	 
	 	 
	 	Name	 
	 	 
	 	Title	 
	 	 

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]